Headquartered in South San Francisco, CA Fiscal year ends December NASDAQ: ALXO alxoncology.com
ALX Oncology Holdings Inc. (Nasdaq: ALXO) is a clinical-stage biotechnology company focused on developing novel therapies to treat cancer. The company's lead candidate, evorpacept, is a CD47-inhibitor being evaluated in multiple clinical trials, including the Phase 2 ASPEN-09-Breast trial in HER2-positive metastatic breast cancer in combination with trastuzumab and chemotherapy. The company's second pipeline candidate, ALX2004, is an EGFR-targeted antibody-drug conjugate (ADC) with a differentiated mechanism of action currently in Phase 1 dose-escalation in patients with EGFR-expressing solid tumors. ALX Oncology is pre-revenue and funds operations through equity and debt financing, with its clinical programs targeting oncology indications where CD47 inhibition and EGFR-targeted ADC approaches may provide therapeutic benefit. Updated
Tuesday's top analyst upgrades and downgrades included Bed Bath & Beyond, Booking, Carvana, Electronic Arts, EOG Resources, Honeywell, Intercontinental Exchange, Livongo Health, Nucor, Seres Therapeutics and Sunrun.
ALX Oncology Holdings Inc. (Nasdaq: ALXO) is a clinical-stage biotechnology company focused on developing novel therapies to treat cancer.
The Wall Street consensus 12-month price target for ALXO is $4.60.
